{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:01:50Z","timestamp":1781704910337,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s13555-014-0061-2","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T05:20:00Z","timestamp":1409030400000},"page":"157-164","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Ingenol Mebutate: A Succinct Review of a Succinct Therapy"],"prefix":"10.1007","volume":"4","author":[{"given":"David Rhys","family":"Alchin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,27]]},"reference":[{"issue":"1 Suppl 1","key":"61_CR1","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jaad.2012.09.053","volume":"68","author":"B Berman","year":"2013","unstructured":"Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol. 2013;68(1 Suppl 1):S10\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"61_CR2","doi-asserted-by":"crossref","unstructured":"Sotiriou E, Apalla Z, Vrani F, Lallas A, Chovarda E, Ioannides D. Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: a randomized intra individual comparison study. JEADV. 2014.","DOI":"10.1111\/jdv.12538"},{"issue":"7","key":"61_CR3","first-page":"539","volume":"36","author":"A Chia","year":"2007","unstructured":"Chia A, Lim A, Shumack S, Moreno G. Actinic keratoses. Aust Fam Phys. 2007;36(7):539.","journal-title":"Aust Fam Phys"},{"key":"61_CR4","first-page":"15","volume":"9","author":"G Goldenberg","year":"2014","unstructured":"Goldenberg G. Optimal treatment of actinic keratosis. Clin Interv Aging. 2014;9:15\u20136.","journal-title":"Clin Interv Aging"},{"issue":"4","key":"61_CR5","first-page":"172","volume":"93","author":"M Perl","year":"2014","unstructured":"Perl M, Goldenberg G. Field therapy in the treatment of actinic keratosis. Cutis. 2014;93(4):172\u20133.","journal-title":"Cutis"},{"issue":"1","key":"61_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s13555-014-0049-y","volume":"4","author":"A Dodds","year":"2014","unstructured":"Dodds A, Chia A, Shumack S. Actinic keratosis: rationale and management. Dermatol Ther (Heidelb). 2014;4(1):11\u201331.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"61_CR7","doi-asserted-by":"crossref","unstructured":"Lebwohl M, Shumack S, Stein Gold L, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666\u201370.","DOI":"10.1001\/jamadermatol.2013.2766"},{"issue":"2","key":"61_CR8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1440-0960.2010.00626.x","volume":"51","author":"G Siller","year":"2010","unstructured":"Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99\u2013105.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"61_CR9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2310\/7750.2012.12050","volume":"17","author":"AK Gupta","year":"2013","unstructured":"Gupta AK, Paquet M. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers. J Cutan Med Surg. 2013;17(3):173\u20139.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"61_CR10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jaad.2009.01.008","volume":"60","author":"L Anderson","year":"2009","unstructured":"Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol. 2009;60(6):934\u201343.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"61_CR11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaad.2010.12.038","volume":"66","author":"RH Rosen","year":"2012","unstructured":"Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. J Am Acad Dermatol. 2012;66(3):486\u201393.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"61_CR12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40257-013-0023-y","volume":"14","author":"A Samrao","year":"2013","unstructured":"Samrao A, Cockerell CJ. Pharmacotherapeutic management of actinic keratosis: focus on newer topical agents. Am J Clin Dermatol. 2013;14(4):273\u20137.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"61_CR13","first-page":"40","volume":"39","author":"B Fidler","year":"2014","unstructured":"Fidler B, Goldberg T. Ingenol mebutate gel (picato): a novel agent for the treatment of actinic keratoses. Pharm Ther. 2014;39(1):40\u20136.","journal-title":"Pharm Ther"},{"issue":"10","key":"61_CR14","first-page":"1181","volume":"11","author":"M Stahlhut","year":"2012","unstructured":"Stahlhut M, Bertelsen M, Hoyer-Hansen M, Svendsen N, Eriksson AH, Lord JM, et al. Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. JDD. 2012;11(10):1181\u201392.","journal-title":"JDD"},{"issue":"1","key":"61_CR15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/toxins2010174","volume":"2","author":"E Ersvaer","year":"2010","unstructured":"Ersvaer E, Kittang AO, Hampson P, Sand K, Gjertsen BT, Lord JM, et al. The protein kinase C agonist PEP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between efficacy and toxicity. Toxins. 2010;2(1):174\u201394.","journal-title":"Toxins"},{"issue":"2","key":"61_CR16","first-page":"1","volume":"17","author":"RS Fallen","year":"2012","unstructured":"Fallen RS, Gooderham M. Ingenol mebutate: an introduction. Skin Ther Lett. 2012;17(2):1\u20133.","journal-title":"Skin Ther Lett"},{"issue":"1","key":"61_CR17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1440-0960.2008.00497.x","volume":"50","author":"G Siller","year":"2009","unstructured":"Siller G, Gebauer K, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol. 2009;50(1):16\u201322.","journal-title":"Australas J Dermatol"},{"issue":"11","key":"61_CR18","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","volume":"366","author":"M Lebwohl","year":"2012","unstructured":"Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. New Engl J Med. 2012;366(11):1010\u20139.","journal-title":"New Engl J Med"},{"issue":"4","key":"61_CR19","first-page":"35","volume":"7","author":"JS Dosik","year":"2014","unstructured":"Dosik JS, Damstra M, Udell C, Welburn P. Evaluation of the skin sensitization, photo irritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers. J Clin Aesthet Dermatol. 2014;7(4):35\u201342.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1 Suppl 1","key":"61_CR20","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.jaad.2012.09.050","volume":"68","author":"G Martin","year":"2013","unstructured":"Martin G, Swanson N. Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol. 2013;68(1 Suppl 1):S39\u201348.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-014-0061-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T19:20:54Z","timestamp":1498159254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13555-014-0061-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,27]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1007\/s13555-014-0061-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,27]]}}}